Summary
Global Markets Direct’s, ‘Sepsis - Pipeline Review, H2 2016’, provides an overview of the Sepsis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Sepsis
- The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects
- The report assesses Sepsis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sepsis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sepsis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Adrenomed AG
Altor BioScience Corporation
Am-Pharma B.V.
Arch Biopartners, Inc.
Aridis Pharmaceuticals LLC
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
Batu Biologics, Inc.
Biomedica Management Corporation
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cell2B S.A.
Chiesi Farmaceutici SpA
Chiome Bioscience, Inc.
Cilian AG
Cognosci, Inc.
Cytheris SA
Endacea, Inc.
Evec, Inc.
Huons Co., Ltd.
Immune Response BioPharma, Inc.
Immunethep, SA
ImmunNovative Developments SL
InflaRx GmbH
Inotrem S.A.
Integrated BioTherapeutics, Inc.
Lead Discovery Center GmbH
Merck & Co., Inc.
Navigen Pharmaceuticals, Inc.
OncoImmune, Inc.
Opsona Therapeutics Limited
Orion Oyj
ProThera Biologics, LLC.
Ra Pharmaceuticals, Inc.
Recce Pty Ltd
Ribomic Inc.
Shionogi & Co., Ltd.
Silence Therapeutics Plc
SK Biopharmaceuticals Co., Ltd.
Stemedica Cell Technologies, Inc.
Syntiron LLC
TaiRx, Inc.
Takeda Pharmaceutical Company Limited
Therakind Limited
Therashock, LLC
TiGenix NV
VBS Pharmaceuticals
ViiV Healthcare Limited
XImmune AB
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Sepsis Overview 11
Therapeutics Development 12
Pipeline Products for Sepsis - Overview 12
Pipeline Products for Sepsis - Comparative Analysis 13
Sepsis - Therapeutics under Development by Companies 14
Sepsis - Therapeutics under Investigation by Universities/Institutes 19
Sepsis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Sepsis - Products under Development by Companies 25
Sepsis - Products under Investigation by Universities/Institutes 30
Sepsis - Companies Involved in Therapeutics Development 31
Adrenomed AG 31
Altor BioScience Corporation 32
Am-Pharma B.V. 33
Arch Biopartners, Inc. 34
Aridis Pharmaceuticals LLC 35
Asahi Kasei Pharma Corp. 36
Astellas Pharma Inc. 37
Batu Biologics, Inc. 38
Biomedica Management Corporation 39
Boehringer Ingelheim GmbH 40
Bristol-Myers Squibb Company 41
Cell2B S.A. 42
Chiesi Farmaceutici SpA 43
Chiome Bioscience, Inc. 44
Cilian AG 45
Cognosci, Inc. 46
Cytheris SA 47
Endacea, Inc. 48
Evec, Inc. 49
Huons Co., Ltd. 50
Immune Response BioPharma, Inc. 51
Immunethep, SA 52
ImmunNovative Developments SL 53
InflaRx GmbH 54
Inotrem S.A. 55
Integrated BioTherapeutics, Inc. 56
Lead Discovery Center GmbH 57
Merck & Co., Inc. 58
Navigen Pharmaceuticals, Inc. 59
OncoImmune, Inc. 60
Opsona Therapeutics Limited 61
Orion Oyj 62
ProThera Biologics, LLC. 63
Ra Pharmaceuticals, Inc. 64
Recce Pty Ltd 65
Ribomic Inc. 66
Shionogi & Co., Ltd. 67
Silence Therapeutics Plc 68
SK Biopharmaceuticals Co., Ltd. 69
Stemedica Cell Technologies, Inc. 70
Syntiron LLC 71
TaiRx, Inc. 72
Takeda Pharmaceutical Company Limited 73
Therakind Limited 74
Therashock, LLC 75
TiGenix NV 76
VBS Pharmaceuticals 77
ViiV Healthcare Limited 78
XImmune AB 79
Sepsis - Therapeutics Assessment 80
Assessment by Monotherapy Products 80
Assessment by Target 81
Assessment by Mechanism of Action 84
Assessment by Route of Administration 87
Assessment by Molecule Type 89
Drug Profiles 91
3K3A-APC - Drug Profile 91
7-H9 - Drug Profile 93
AB-022 - Drug Profile 94
AcPepA - Drug Profile 95
adrecizumab - Drug Profile 96
ALT-836 - Drug Profile 97
AM/AMBP-1 - Drug Profile 99
Aspidasept - Drug Profile 100
Atu-111 - Drug Profile 101
BI-113823 - Drug Profile 102
Biologic to Inhibit PD-L1 for Immunology - Drug Profile 103
BMS-936559 - Drug Profile 104
BMS-986189 - Drug Profile 107
BRL-44408 - Drug Profile 108
BTZO-2 - Drug Profile 109
CAR Peptide - Drug Profile 110
ceftaroline fosamil - Drug Profile 111
COG-133 - Drug Profile 114
Cx-611 - Drug Profile 116
CYT-107 - Drug Profile 120
Drug for Sepsis and Septic Shock - Drug Profile 123
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 124
Drugs to Inhibit Sialidase for Sepsis - Drug Profile 125
Escherichia coli vaccine - Drug Profile 126
ethinyl estradiol sulfonate - Drug Profile 127
EV-007156 - Drug Profile 128
Gamma-PN - Drug Profile 129
Glyco-23 - Drug Profile 130
HBN-1 - Drug Profile 131
HBN-3 - Drug Profile 132
HBN-4 - Drug Profile 133
HU-003 - Drug Profile 134
IFX-1 - Drug Profile 135
ImmStem - Drug Profile 137
ImmuneSafe - Drug Profile 138
IMT-504 - Drug Profile 139
IND-006 - Drug Profile 141
IR-999 - Drug Profile 142
Klebsiella pneumoniae vaccine - Drug Profile 143
L-257 - Drug Profile 144
L-97-1 - Drug Profile 145
L-Citrulline - Drug Profile 147
levosimendan - Drug Profile 148
M-33 - Drug Profile 152
M-6229 - Drug Profile 153
meropenem - Drug Profile 154
Metablok - Drug Profile 155
Micselon - Drug Profile 156
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 157
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 158
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 159
Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile 160
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 161
Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile 162
Motrem - Drug Profile 163
NAV-838 - Drug Profile 164
OPN-305 - Drug Profile 165
OTP-300 - Drug Profile 167
Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis - Drug Profile 168
PNV-1 - Drug Profile 169
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 170
RA-101295 - Drug Profile 171
RBM-005 - Drug Profile 172
RECCE-327 - Drug Profile 173
Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile 174
Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile 175
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 178
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 179
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 180
Recombinant Protein for Inflammation and Bacterial Sepsis - Drug Profile 181
Recombinant Protein for Sepsis - Drug Profile 182
Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile 183
S-649266 - Drug Profile 184
SAN-101 - Drug Profile 186
Slit2N - Drug Profile 187
Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 188
Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile 189
Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 190
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 191
Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile 192
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 193
Staphylococcus aureus (multivalent) vaccine - Drug Profile 194
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 195
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 197
Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 202
Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 203
Synthetic Peptides for Infectious Disease - Drug Profile 204
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 205
Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile 206
Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 207
Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile 208
TF-0003 - Drug Profile 209
thrombomodulin alfa - Drug Profile 210
tosatoxumab - Drug Profile 212
TRX-306 - Drug Profile 214
vancomycin hydrochloride - Drug Profile 215
Yersinia pestis vaccine - Drug Profile 216
Sepsis - Dormant Projects 217
Sepsis - Discontinued Products 222
Sepsis - Product Development Milestones 223
Featured News & Press Releases 223
Appendix 232
Methodology 232
Coverage 232
Secondary Research 232
Primary Research 232
Expert Panel Validation 232
Contact Us 232
Disclaimer 233
List of Tables
Number of Products under Development for Sepsis, H2 2016 19
Number of Products under Development for Sepsis - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 22
Number of Products under Development by Companies, H2 2016 (Contd..1) 23
Number of Products under Development by Companies, H2 2016 (Contd..2) 24
Number of Products under Development by Companies, H2 2016 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2016 27
Comparative Analysis by Late Stage Development, H2 2016 28
Comparative Analysis by Clinical Stage Development, H2 2016 29
Comparative Analysis by Early Stage Development, H2 2016 30
Comparative Analysis by Unknown Stage Development, H2 2016 31
Products under Development by Companies, H2 2016 32
Products under Development by Companies, H2 2016 (Contd..1) 33
Products under Development by Companies, H2 2016 (Contd..2) 34
Products under Development by Companies, H2 2016 (Contd..3) 35
Products under Development by Companies, H2 2016 (Contd..4) 36
Products under Investigation by Universities/Institutes, H2 2016 37
Sepsis - Pipeline by Adrenomed AG, H2 2016 38
Sepsis - Pipeline by Altor BioScience Corporation, H2 2016 39
Sepsis - Pipeline by Am-Pharma B.V., H2 2016 40
Sepsis - Pipeline by Arch Biopartners, Inc., H2 2016 41
Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 42
Sepsis - Pipeline by Asahi Kasei Pharma Corp., H2 2016 43
Sepsis - Pipeline by Astellas Pharma Inc., H2 2016 44
Sepsis - Pipeline by Batu Biologics, Inc., H2 2016 45
Sepsis - Pipeline by Biomedica Management Corporation, H2 2016 46
Sepsis - Pipeline by Boehringer Ingelheim GmbH, H2 2016 47
Sepsis - Pipeline by Bristol-Myers Squibb Company, H2 2016 48
Sepsis - Pipeline by Cell2B S.A. , H2 2016 49
Sepsis - Pipeline by Chiesi Farmaceutici SpA, H2 2016 50
Sepsis - Pipeline by Chiome Bioscience, Inc., H2 2016 51
Sepsis - Pipeline by Cilian AG, H2 2016 52
Sepsis - Pipeline by Cognosci, Inc., H2 2016 53
Sepsis - Pipeline by Cytheris SA, H2 2016 54
Sepsis - Pipeline by Endacea, Inc., H2 2016 55
Sepsis - Pipeline by Evec, Inc., H2 2016 56
Sepsis - Pipeline by Huons Co., Ltd., H2 2016 57
Sepsis - Pipeline by Immune Response BioPharma, Inc., H2 2016 58
Sepsis - Pipeline by Immunethep, SA, H2 2016 59
Sepsis - Pipeline by ImmunNovative Developments SL, H2 2016 60
Sepsis - Pipeline by InflaRx GmbH, H2 2016 61
Sepsis - Pipeline by Inotrem S.A., H2 2016 62
Sepsis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016 63
Sepsis - Pipeline by Lead Discovery Center GmbH, H2 2016 64
Sepsis - Pipeline by Merck & Co., Inc., H2 2016 65
Sepsis - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 66
Sepsis - Pipeline by OncoImmune, Inc., H2 2016 67
Sepsis - Pipeline by Opsona Therapeutics Limited, H2 2016 68
Sepsis - Pipeline by Orion Oyj, H2 2016 69
Sepsis - Pipeline by ProThera Biologics, LLC., H2 2016 70
Sepsis - Pipeline by Ra Pharmaceuticals, Inc., H2 2016 71
Sepsis - Pipeline by Recce Pty Ltd, H2 2016 72
Sepsis - Pipeline by Ribomic Inc., H2 2016 73
Sepsis - Pipeline by Shionogi & Co., Ltd., H2 2016 74
Sepsis - Pipeline by Silence Therapeutics Plc, H2 2016 75
Sepsis - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 76
Sepsis - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 77
Sepsis - Pipeline by Syntiron LLC, H2 2016 78
Sepsis - Pipeline by TaiRx, Inc., H2 2016 79
Sepsis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 80
Sepsis - Pipeline by Therakind Limited, H2 2016 81
Sepsis - Pipeline by Therashock, LLC, H2 2016 82
Sepsis - Pipeline by TiGenix NV, H2 2016 83
Sepsis - Pipeline by VBS Pharmaceuticals, H2 2016 84
Sepsis - Pipeline by ViiV Healthcare Limited, H2 2016 85
Sepsis - Pipeline by XImmune AB, H2 2016 86
Assessment by Monotherapy Products, H2 2016 87
Number of Products by Stage and Target, H2 2016 89
Number of Products by Stage and Mechanism of Action, H2 2016 92
Number of Products by Stage and Route of Administration, H2 2016 95
Number of Products by Stage and Molecule Type, H2 2016 97
Sepsis - Dormant Projects, H2 2016 224
Sepsis - Dormant Projects (Contd..1), H2 2016 225
Sepsis - Dormant Projects (Contd..2), H2 2016 226
Sepsis - Dormant Projects (Contd..3), H2 2016 227
Sepsis - Dormant Projects (Contd..4), H2 2016 228
Sepsis - Discontinued Products, H2 2016 229
List of Figures
Number of Products under Development for Sepsis, H2 2016 19
Number of Products under Development for Sepsis - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Clinical Stage Development, H2 2016 29
Comparative Analysis by Early Stage Products, H2 2016 30
Assessment by Monotherapy Products, H2 2016 87
Number of Products by Top 10 Targets, H2 2016 88
Number of Products by Stage and Top 10 Targets, H2 2016 88
Number of Products by Top 10 Mechanism of Actions, H2 2016 91
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 91
Number of Products by Top 10 Routes of Administration, H2 2016 94
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 94
Number of Products by Top 10 Molecule Types, H2 2016 96
Number of Products by Stage and Top 10 Molecule Types, H2 2016 96
